Key Statistics for SNTS
|Current P/E Ratio (ttm)
Relative P/E vs.
|Earnings Per Share (USD) (ttm)
|Est. EPS (USD) (12/2013)
|Est. PEG Ratio
|Market Cap (M USD)
|Shares Outstanding (M)
|30 Day Average Volume
|Dividend Indicated Gross Yield
|5 Year Dividend Growth
|Next Earnings Announcement
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for SNTS
- Net Income (M/USD)
Santarus Inc. is a pharmaceutical company focused on acquiring, developing and commercializing proprietary products for patients treated by gastroenterologists and other physicians. The company currently markets products for the treatment of upper GI diseases and disorders and type 2 diabetes, and is developing drugs for the treatment of lower GI disorders.
More Company Profile & Key Executives for SNTS
|Gerald T ProehlPresident/CEO||Wendell D WierengaExec VP:Research & Dev|
|Debra P CrawfordSenior VP/CFO/Treasurer/Secy||William C Denby IIISenior VP:Commercial Ops|
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries